Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000-2016: a Danish population-based study.

British Journal of Haematology
Lasse Hjort JakobsenMarianne Tang Severinsen

Abstract

In the present study, we quantify the progress in overall survival (OS) during the period 2000-2016 among Danish patients with acute myeloid leukaemia (AML). This population-based study, including 3820 adult patients with AML, demonstrates a significantly improved OS over time with the 2-year age-standardised OS increasing from 22% in 2002 to 31% in 2016. The improvement in OS was exclusively seen in patients with AML aged ≥50 years, with absolute improvements in 2-year OS from 2002 to 2016 of ≥10% among patients aged 50-75 years and a small absolute increase in those aged >75 years.

References

Sep 20, 2002·Blood·James W VardimanRichard D Brunning
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan BurnettBob Löwenberg
Mar 26, 2011·Blood·Gunnar Juliusson, UNKNOWN Swedish AML Group
Aug 24, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M F FeyUNKNOWN ESMO Guidelines Working Group
Aug 16, 2015·BMC Medical Research Methodology·Paul C LambertMark J Rutherford
Sep 3, 2016·Statistical Methods in Medical Research·Xing-Rong LiuMark Clements
Nov 9, 2016·Clinical Epidemiology·Lene Sofie Granfeldt ØstgårdLone Smidstrup Friis

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.